Research programme: peptide therapeutics - BioLineRx/Compugen

Drug Profile

Research programme: peptide therapeutics - BioLineRx/Compugen

Alternative Names: BL-7060; BL-8010; CGEN-25017; CGEN-855; CGEN-856; EDP 29; EDP 30

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Compugen
  • Developer BioLineRx
  • Class Peptides
  • Mechanism of Action Angiogenesis inhibitors; Angiopoietin inhibitors; G protein-coupled receptor agonists; RXFP1 protein stimulants; TIE 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Myocardial infarction
  • Discontinued Retinal disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Myocardial-infarction in Israel
  • 01 Mar 2013 Discontinued - Preclinical for Retinal disorders in Israel (unspecified route)
  • 13 Dec 2011 Preclinical trials in Retinal disorders in Israel (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top